Tagged with GC

Saudi Arabia Baxter Saudia Arabia GM Faisal BinDail shares some insights into the renal care specialist’s local manufacturing hub, the sole manufacturing site for peritoneal dialysis products in the Middle East, and the company’s plans to expand its reach in Saudi Arabia and the broader region.   We aim to provide our…

Saudi Arabia Basel Al-Qahtani, General Manager of Boston Scientific Saudi Arabia, discusses how Boston Scientific has expanded its operations to establish a fully fledged regional headquarters in the kingdom. He outlines the company’s commitment to Saudi Arabia’s Vision 2030 agenda through public-private partnerships and potentially through accountable care organizations, and underlines the…

UAE Sovereign wealth funds (SWFs) in the Gulf Cooperation Council (GCC) countries are increasingly investing in healthcare and the life sciences to reinforce their local industries and pursue the region’s economic diversification goals. Following the Saudi fund PIF’s launch of CDMO Lifera and Qatar’s QIA biotech investments, the UAE fund ADQ…

Saudi Arabia Founded in 2016, the groundbreaking healthtech start-up Aumet has set out to digitize the procurement cycle within the pharmaceutical sector with its AI-enabled business-to-business healthcare platform. Co-founder and managing director for Saudi Arabia, Mohamed Mazen Batterjee, explains the strong foothold the company has established in the region and how its…

Saudi Arabia Halal pharmaceuticals, or medicines produced according to Islamic dietary laws, presented a global market worth some USD 100 billion in 2019, yet much of halal pharmaceuticals’ potential remains untapped. In conversation with PharmaBoardroom, Mazen M. Hassanain, co-founder and managing director of SaudiVax, a pioneer in halal vaccines, discusses the development…

Portugal While not a major player in clinical trials at the European level, Portugal has untapped potential in this field, leveraging a first pioneering centre in Braga, the country’s strong scientific community, a growing openness to collaboration with industry, and access to a European patient database. Considering the remarkable progress that…

Portugal Monica Bettencourt-Dias of the Gulbenkian Institute for Science highlights the IGC’s pioneering role in biological sciences, supporting scientists and innovators who have significantly contributed to the field globally for over 63 years. She also touches on Portugal’s scientific excellence, how the IGC is balancing fundamental research with initiatives for technology…

Saudi Arabia As the GCC’s largest market, Saudi Arabia, with its growing population, strong healthcare infrastructure and government commitment to developing the economy beyond oil through its Vision 2030, is increasingly attractive for multinational pharma and local players alike. In 2024 government reforms will continue to encourage investment and local production while…

Global Mohamed Meshref M.D, PhD is a Professor of Oncology at Cairo University and Regional Medical Director at Boehringer Ingelheim for India, Middle East, Turkey & Africa (IMETA). Here, Prof. Meshref discusses the importance of an ‘early medical affairs mindset’ within the pharma industry whereby medical affairs personnel engage much earlier…

UAE MSD GCC’s Ashraf Mallak looks back on a “transformational” two years since his last PharmaBoardroom interview back in 2021, with the set up of a new regional office, a raft of new launches and expanded indications, and the landmark inclusion of its HPV vaccine on various national immunization programs. Mallak…

UAE Erstwhile general manager for the GCC countries at Japanese-headquartered rare disease specialist Kyowa Kirin, earlier this year Myriam Hakim was appointed as the firm’s regional nephrology franchise head for the entire EMEA region. Here, Hakim discusses some of the key challenges she navigated the GCC grouping through over the past…

UAE Ahmed Moustafa outlines the incredible development of the healthcare ecosystem in the UAE driven by a rapid ramping up of the country’s health infrastructure and a willingness on the part of the authorities to enter into partnerships with leading private sector players like Amgen. He also touches on the major…